Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.4
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2020
Jun. 30, 2020
Current assets:    
Cash and cash equivalents $ 91,252,000 $ 55,112,000
Accounts receivable - trade 180,000 75,000
Accounts receivable - other 52,000 0
Subscription receivable 0 5,549,000
Investments in debt securities 16,395,000 0
Work in process 1,071,000 798,000
Prepaid expenses and other current assets 1,932,000 214,000
Total Current Assets 110,882,000 61,748,000
Convertible promissory note receivable and accrued interest 1,519,000 0
Finance lease right-of-use assets, net of accumulated amortization 26,786,000 27,616,000
Fixed assets, net of accumulated depreciation 5,010,000 3,657,000
Intangible assets, net of accumulated amortization 1,185,000 1,144,000
Security deposits 24,000 24,000
Total Assets 145,406,000 94,189,000
Current liabilities:    
Accounts payable (related parties of $94 and $6 as of December 31, 2020 and June 30, 2020, respectively) 2,409,000 1,759,000
Accrued expenses (related party of $703 and $705 as of December 31, 2020 and June 30, 2020, respectively) 1,683,000 1,105,000
Note payable - PPP Loan - current portion 465,000 261,000
Finance lease obligation - current portion 312,000 301,000
Contract liabilities 1,233,000 1,810,000
Total Current Liabilities 6,102,000 5,236,000
Note payable - PPP Loan - net of current portion 135,000 339,000
Finance lease obligation - net of current portion 31,848,000 32,007,000
Total Liabilities 38,085,000 37,582,000
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 and 275,000,000 shares authorized at December 31, 2020 and June 30, 2020, respectively; 211,769,103 and 140,071,110 shares issued and outstanding as of December 31, 2020 and June 30, 2020, respectively 212,000 140,000
Additional paid-in capital 273,258,000 206,931,000
Accumulated other comprehensive loss (53,000) (33,000)
Accumulated deficit (166,082,000) (150,420,000)
Total iBio, Inc. Stockholders' Equity 107,335,000 56,618,000
Noncontrolling interest (14,000) (11,000)
Total Equity 107,321,000 56,607,000
Total Liabilities and Equity 145,406,000 94,189,000
iBio CMO    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0